Only IZERVAY directly targets C5, preserving upstream homeostasis of the complement system7,18

Designed differently19

SYNTHETICALLY DEVELOPED

RNA aptamer technology

Icon of a shield and cells

Low immunogenicity 

Low likelihood of inducing an immune response.

Icon depicting binding affinity

High binding affinity 

Strong and specific inhibition of the target. 

Targets differently7,20

Icon of C5 in a circle with a line through it

By inhibiting C5, IZERVAY may:

  • Reduce inflammation
  • Reduce retinal cell death
  • Reduce loss of photoreceptors

Comprehensive packaging for seamless administration7

Image of Izervay packaging Image of Izervay packaging

Preparation and administration

Icon of a needle

IZERVAY can be administered with a 30-gauge injection needle, which may decrease patient discomfort.7,21

Icon of a vial

For added convenience in your practice, unopened vials of IZERVAY can remain unrefrigerated for up to 24 hours.7

Download our Administration Brochure

RNA=ribonucleic acid.

When you see GA, start IZERVAY

Next page
IMPORTANT SAFETY INFORMATION AND INDICATION
IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindications
  • IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
Warnings and Precautions
  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
  • Increase in Intraocular Pressure
    • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
Adverse Reactions
  • Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.